[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354848-105":59,"doc-detail-354848-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","elucidating-cooperative-genetic-events-in-dcis-progression-in-mutant-p53driven-breast-cancer","Elucidating cooperative genetic events in DCIS progression in mutant p53–driven breast cancer","","Ductal carcinoma in situ (DCIS) is a precursor mammary lesion confined to ductal luminal space, yet many lesions do not become invasive and no clinical approach reliably separates indolent from progressive DCIS. The study uses an autochthonous Trp53R245W somatic mouse model and genomic sequencing to find shared changes between DCIS and invasive tumors, then tests candidate genes in human breast cells. Functional assays show TMEM267 cooperates with mutant TP53, increasing DCIS-like phenotypes and suggesting potential treatment opportunities.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/elucidating-cooperative-genetic-events-in-dcis-progression-in-mutant-p53driven-breast-cancer/354848/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/elucidating-cooperative-genetic-events-in-dcis-progression-in-mutant-p53driven-breast-cancer/354848.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is stratifying indolent DCIS from progressive DCIS clinically difficult?","Question",{"text":112,"@type":113},"Not all DCIS becomes invasive, and current care does not provide a strategy to distinguish indolent lesions from those at risk of progression, leading to overtreatment for many patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What models and sequencing approaches were used to identify cooperating events?",{"text":117,"@type":113},"The work uses an autochthonous somatic mouse model of Trp53R245W-driven breast cancer and applies exome sequencing and low-pass whole-genome sequencing to uncover genomic changes shared between DCIS and invasive tumors.",{"name":119,"@type":110,"acceptedAnswer":120},"How was TMEM267 evaluated in relation to mutant TP53?",{"text":121,"@type":113},"The study assessed cooperativity with mutant TP53 in human breast cells using acinar morphogenesis and migration assays; overexpression of TMEM267 with mutant TP53 produced a significant increase in a filled duct, DCIS-like phenotype.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354848,1790168963,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","Elucidating cooperative genetic events in DCIS progression in mutant p53–driven breast cancer  \nRhiannon L. Morrisseya, b, Joy M. McDanielb, Gilda P. Chaub , Xiaoping Suc, Mitheera Va, b, Vidhi Chandrab, Beverly R. E. A. Dixonb, Adel K. El-Naggard,  \nAlastair M. Thompsone, and Guillermina Lozanoa, b, 1  Affiliations are included on p. 10.  \nContributed by Guillermina Lozano; received September 19, 2025; accepted December 7, 2025; reviewed by James G. Jackson and Senthil K. Muthuswamy  \nDuctal carcinoma in situ (DCIS) is a precursor mammary lesion characterized by abnormal epithelial cells in mammary ducts that remain confined to the luminal space. Not all DCIS becomes invasive, and no strategy currently exists in patients tostratify indolent DCIS from DCIS at risk of progression. Several studies of human DCIS and breast cancer suggest that TP53 mutations occur early in DCIS. However, TP53 mutation alone is insufficient for DCIS formation or transformation to invasive disease. Using an autochthonous somatic mouse model of Trp53R245Winduced breast cancer (equivalent to the TP53R248W hotspot mutation in humans), we identified DCIS lesions. Through exome sequencing and low-pass whole-genome sequencing, we identified additional genomic changes shared between DCIS and invasive tumors. This comparison nominated seven murine candidate genes, with eight human orthologs. We assessed the cooperativity of these genes with mutant TP53 in human breast cells using acinar morphogenesis and migration assays. Overexpression of TMEM267, which encodes a transmembrane protein overexpressed in 22% of TP53 missense mutant breast cancer cases, in cells with mutant TP53 caused a significant increase in the filled duct, DCIS-like phenotype. We nominate TMEM267 as a cooperating event with mutant TP53 in DCIS progression.  \nDCIS | breast cancer | mutant p53 | mouse models  \nDuctal carcinoma in situ (DCIS) is a neoplasm of abnormal epithelial cells occurring in, but still confined to, the luminal space of the mammary ducts ( 1) . These lesions are detected upon mammography, often as microcalcifications in the DCIS-containing ducts (2, 3). 20 to 25% of mammogram-detected lesions are DCIS (4) . DCIS can progress into an invasive tumor if the myoepithelium becomes compromised and the neoplastic cells previously confined to the lumen invade. However, not all DCIS becomes invasive, and no strategy currently exists to stratify indolent DCIS from DCIS at risk of progression (4–7). The standard of care for DCIS is surgical removal, as well as radiation and hormone therapy, if applicable (4, 8) . Since not all DCIS progresses to invasion, this standard regimen constitutes overtreatment for many women; unfortunately, this paradigm seems likely to persist until a better progression risk prediction strategy is devised (9) .  \nSeveral recent studies have sequenced DCIS lesions and identified mutations in TP53 . Some of these studies have sequenced pure DCIS with no invasive region (total 83 lesions)( 10–13) . Other studies have sampled synchronous DCIS, occurring in tandem with invasive disease, as well as preceding DCIS occurring years before an ensuing invasive lesion (total 37 lesions) (6, 12, 13). These studies identified TP53 mutations at frequencies of 11 to 60%(6, 11–13) . TP53 mutations were also shared between DCIS and invasive breast cancer (6, 14), which suggests that although TP53 is necessary for tumorigenesis, it is not sufficient on its own to cause tumor development.  \nThe tumor suppressor Trp53 responds to cellular damage and stress and binds to DNA in a sequence-specific manner, triggering the transcription of genes effectuating certain outcomes including apoptosis, cell cycle arrest, and senescence (15). This signaling cascade prevents damaged and aberrant cells from being able to proliferate, thereby implementing p53 tumor suppression.  \nTP53 is a commonly mutated gene across many cancer types, including breast cancer ( 16, 17) . TP53 is mutated in","cbCaiiQkNiEvj09Z","https://ap.wps.com/l/cbCaiiQkNiEvj09Z","pdf",2964538,11,"English","# Significance\n## DCIS background and clinical challenge\n## TP53 mutations in DCIS and tumorigenesis\n## p53 function and stress response\n## Candidate gene identification and functional validation","[{\"question\":\"Why is stratifying indolent DCIS from progressive DCIS clinically difficult?\",\"answer\":\"Not all DCIS becomes invasive, and current care does not provide a strategy to distinguish indolent lesions from those at risk of progression, leading to overtreatment for many patients.\"},{\"question\":\"What models and sequencing approaches were used to identify cooperating events?\",\"answer\":\"The work uses an autochthonous somatic mouse model of Trp53R245W-driven breast cancer and applies exome sequencing and low-pass whole-genome sequencing to uncover genomic changes shared between DCIS and invasive tumors.\"},{\"question\":\"How was TMEM267 evaluated in relation to mutant TP53?\",\"answer\":\"The study assessed cooperativity with mutant TP53 in human breast cells using acinar morphogenesis and migration assays; overexpression of TMEM267 with mutant TP53 produced a significant increase in a filled duct, DCIS-like phenotype.\"}]","Elucidating cooperative genetic events in DCIS progression in mutant p53–driven breast cancer | PDF",1790114412,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0fcb027e408d615d7387ea0cbf456c0a.webp",983,1316,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/42276b758709cd7ef0dc8c1c00a7c7b6.webp",982,1315,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fdb43e266873f42786f721a4c4a5f7f0.webp",981,1313,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b183e1915d02141b88e6d10ee18335c5.webp",980,1312]